Allergan contact lens care business posts 16% third-quarter sales increase.
This article was originally published in The Tan Sheet
Executive Summary
ALLERGAN CONTACT LENS CARE SALES RISE 15.7% TO $104.7 MIL. in the third quarter ended Sept. 30, the company reported Oct. 16. However, excluding $13 mil. in sales from Pilkington Barnes Hind products acquired in the fourth quarter of 1995, Allergan's lens care sales increased only 1%. Optical lens care is Allergan's largest segment, generating 36.4% of total sales
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.